Details

Autor(en) / Beteiligte

• Balcázar-Valencia, Carlos Mario
• García-Ramos, Andrés Felipe
• Osorio-Toro, Luis Miguel
• Ordoñez-Guzmán, Yessica Alejandra
• Buitrago-Gómez, Nathalia
• Cabarcas-López, William Fernando
• Vizcaino-Guerrero, Carlos Javier
• Daza-Arana, Jorge Enrique
• Ramírez-Rincón, Alex
• Restrepo-Erazo, Katherine

Titel

Semaglutide Effects on Metabolic Outcomes in Diabetes Mellitus Patients - Real World Study

Ist Teil von

• Diabetes, metabolic syndrome and obesity, 2024-01, Vol.17, p.1667-1673

Ort / Verlag

New Zealand: Dove Medical Press Limited

Erscheinungsjahr

2024

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Diabetes is a public health problem that requires strategies to impact glycemic control and reduce the risk of long-term medical complications. Pharmacological management is a necessary treatment for this disease. Therefore, semaglutide is an essential tool to achieve the treatment targets. The present study aimed to evaluate the semaglutide effects on a cohort with type 2 diabetes mellitus (T2DM) in Colombia. The cohort included 49 patients with T2DM that have been treated in a specialized care center. Their glycemic outcomes, weight, renal function, and adverse events were evaluated through a 3-, 6- and 12-month follow-up. Significant differences were observed in the outcome evaluation: reduction of glycated hemoglobin levels (MD -2.74 CI -1.95 to -3.52 in 6 months), fasting plasma glucose levels, body weight (MD -7.11 CI -5.97 to -8.24), and the albumin-to-creatinine ratio. The results were maintained throughout the treatment period. The adverse event rate was 16.3%, predominating gastrointestinal events. This real-world evidence shows the efficacy of semaglutide in achieving treatment goals in patients with T2DM.